4//SEC Filing
Davidson Michael H. 4
Accession 0001654954-24-010192
CIK 0000034956other
Filed
Aug 7, 8:00 PM ET
Accepted
Aug 8, 7:42 PM ET
Size
13.3 KB
Accession
0001654954-24-010192
Insider Transaction Report
Form 4
Davidson Michael H.
Director
Transactions
- Purchase
Pre-Funded Warrant
2024-08-08+47,500→ 47,500 totalExercise: $0.01From: 2024-08-08→ Common Stock (47,500 underlying) - Purchase
Common Stock
2024-08-08+2,500→ 2,881 total - Purchase
Warrant
2024-08-08+25,000→ 25,000 totalExercise: $4.50From: 2024-08-08→ Common Stock (25,000 underlying)
Holdings
- 4
Stock Option (right to buy)
Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying) - 4
Stock Option (right to buy)
Exercise: $3200.00From: 2022-06-10Exp: 2032-06-10→ Common Stock (4 underlying)
Footnotes (6)
- [F1]. On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99.
- [F2]The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F3]The pre-funded warrant has no expiration date.
- [F4]The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
- [F5]These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F6]These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001573785
Filing Metadata
- Form type
- 4
- Filed
- Aug 7, 8:00 PM ET
- Accepted
- Aug 8, 7:42 PM ET
- Size
- 13.3 KB